東華大學圖書館 |

Language: English

Help

回圖書館首頁

手機版館藏查詢

Back

Switch To: Labeled | MARC Mode | ISBD

Poly(2-Oxazoline) Micellar Formulati...

Wan, Xiaomeng.

Linked to FindBook

Google Book

Amazon

博客來

Poly(2-Oxazoline) Micellar Formulation For Cancer Therapy.

Record Type:	Electronic resources : Monograph/item
Title/Author:	Poly(2-Oxazoline) Micellar Formulation For Cancer Therapy./
Author:	Wan, Xiaomeng.
Published:	Ann Arbor : ProQuest Dissertations & Theses, : 2018,
Description:	217 p.
Notes:	Source: Dissertations Abstracts International, Volume: 79-12, Section: B.
Contained By:	Dissertations Abstracts International79-12B.
Subject:	Pharmaceutical sciences. -
Online resource:	http://pqdd.sinica.edu.tw/twdaoapp/servlet/advanced?query=10750842
ISBN:	9780438033764

Poly(2-Oxazoline) Micellar Formulation For Cancer Therapy.
Wan, Xiaomeng.

Poly(2-Oxazoline) Micellar Formulation For Cancer Therapy. - Ann Arbor : ProQuest Dissertations & Theses, 2018 - 217 p.

Source: Dissertations Abstracts International, Volume: 79-12, Section: B.

Thesis (Ph.D.)--The University of North Carolina at Chapel Hill, 2018.

This item must not be sold to any third party vendors.

Most nanoparticles have a fairly low threshold for incorporation of such drugs. Previously, we have reported a nanosized polymeric micelles (PM) formulation based on highly defined amphiphilic triblock copolymers of poly(2-oxazoline)s (POx), poly(2-methyl-2-oxazoline-block-2-butyl-2-oxazoline-block-2-methyl-2-oxazoline) (P(MeOx-b-BuOx-b-MeOx)), that have greatly enhanced the solubility of single and multiple drug combinations. In particular, the POx-based PM of paclitaxel (PTX) with unprecedentedly high drug loading of nearly 45 % wt. and controllable ∼30 to 40 nm size displayed reduced toxicity and superior efficacy in early and late stage breast cancer models compared to clinically approved Taxol and Abraxane. The co-delivery of drugs in a single nanofomulation remains a principal challenge since poor solubility and differential pharmacokinetics (PK) severely restricts the selection of drugs that can be translated into successful combination treatments. Critical to success is optimizing the relative doses of the drugs to obtain synergistic effects on tumors [4]. Here, we propose that co-loading of PTX and hydrophobic cisplatin prodrug at synergistic drugs ratios in the POx-based drug delivery platform significantly improve the PK profile and efficacy in both ovarian and breast cancer. We also propose that co-loading of etoposide (ETO) and platinate at synergistic drugs ratios in the POx-based drug delivery platform with "worm-like" shape micelles can safely and efficiently treat both SCLC and NSCLC lung cancer. In summary, tri-block POx copolymer is a viable and promising platform for various chemotherapeutic agents, singly and multiply, delivery in cancer therapy.

ISBN: 9780438033764Subjects--Topical Terms:

3173021
Pharmaceutical sciences.

Poly(2-Oxazoline) Micellar Formulation For Cancer Therapy.
LDR:02756nmm a2200313 4500 001 2210324
005 20191121124204.5
008 201008s2018 ||||||||||||||||| ||eng d
020 $a 9780438033764
035 $a (MiAaPQ)AAI10750842
035 $a (MiAaPQ)unc:17542
035 $a AAI10750842
040 $a MiAaPQ $c MiAaPQ
100 1 $a Wan, Xiaomeng. $3 3437465
245 1 0 $a Poly(2-Oxazoline) Micellar Formulation For Cancer Therapy.
260 1 $a Ann Arbor : $b ProQuest Dissertations & Theses, $c 2018
300 $a 217 p.
500 $a Source: Dissertations Abstracts International, Volume: 79-12, Section: B.
500 $a Publisher info.: Dissertation/Thesis.
500 $a Advisor: Kabanov, Alexander V.
502 $a Thesis (Ph.D.)--The University of North Carolina at Chapel Hill, 2018.
506 $a This item must not be sold to any third party vendors.
520 $a Most nanoparticles have a fairly low threshold for incorporation of such drugs. Previously, we have reported a nanosized polymeric micelles (PM) formulation based on highly defined amphiphilic triblock copolymers of poly(2-oxazoline)s (POx), poly(2-methyl-2-oxazoline-block-2-butyl-2-oxazoline-block-2-methyl-2-oxazoline) (P(MeOx-b-BuOx-b-MeOx)), that have greatly enhanced the solubility of single and multiple drug combinations. In particular, the POx-based PM of paclitaxel (PTX) with unprecedentedly high drug loading of nearly 45 % wt. and controllable ∼30 to 40 nm size displayed reduced toxicity and superior efficacy in early and late stage breast cancer models compared to clinically approved Taxol and Abraxane. The co-delivery of drugs in a single nanofomulation remains a principal challenge since poor solubility and differential pharmacokinetics (PK) severely restricts the selection of drugs that can be translated into successful combination treatments. Critical to success is optimizing the relative doses of the drugs to obtain synergistic effects on tumors [4]. Here, we propose that co-loading of PTX and hydrophobic cisplatin prodrug at synergistic drugs ratios in the POx-based drug delivery platform significantly improve the PK profile and efficacy in both ovarian and breast cancer. We also propose that co-loading of etoposide (ETO) and platinate at synergistic drugs ratios in the POx-based drug delivery platform with "worm-like" shape micelles can safely and efficiently treat both SCLC and NSCLC lung cancer. In summary, tri-block POx copolymer is a viable and promising platform for various chemotherapeutic agents, singly and multiply, delivery in cancer therapy.
590 $a School code: 0153.
650 4 $a Pharmaceutical sciences. $3 3173021
690 $a 0572
710 2 $a The University of North Carolina at Chapel Hill. $b Pharmaceutical Sciences. $3 1285238
773 0 $t Dissertations Abstracts International $g 79-12B.
790 $a 0153
791 $a Ph.D.
792 $a 2018
793 $a English
856 4 0 $u http://pqdd.sinica.edu.tw/twdaoapp/servlet/advanced?query=10750842